Short answer
AtriCure, Inc. (ATRC) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). AtriCure reported first-quarter results for the period ended March 31, 2026.
AtriCure, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- AtriCure reported first-quarter results for the period ended March 31, 2026
- Results discussion scheduled for May 5, 2026 at 4:30 p.m. Eastern Time
- Exhibit 99.1 contains the financial results and management commentary for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 revenue $141.2M, up 14.3% YoY, with U.S. growth accelerating to 14.9%
- Profitability reached $0.1M net income versus a $6.7M loss, while adjusted EBITDA rose 95% to $17.1M
- Gross margin expanded 246 basis points to 77.4%, supported by favorable product and geographic mix
- Growth concentrated in cryoSPHERE MAX, AtriClip FLEX-Mini, AtriClip PRO-Mini MASON, and EnCompass
- 2026 guidance maintained at $600M-$610M revenue and $80M-$82M adjusted EBITDA, with positive cash flow expected
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AtriCure, Inc. 8-K filings
Get the next ATRC 8-K as it lands
Follow ATRC for push alerts, or ask the research agent what this filing means.